The purpose of this study is to see if treatment with H.P. Acthar® Gel will result in the
improvement and long-term stabilization of clinical and radiographic abnormalities that occur
in patients with CNS sarcoidosis. In addition, it will also look at whether treatment will be
also associated with improvement in measures of quality of life. The treatment of CNS
sarcoidosis involves the use of either corticosteroids such as prednisone or potent
immunosuppressive agents such as methotrexate, both which can induce severe long term side
effects. The adverse effects of steroids may be avoided by treatment with adrenocorticotropic
hormone (ACTH), which is available for patient use as H.P. Acthar® Gel. The efficacies of
H.P. Acthar® Gel in the treatment of CNS sarcoidosis and the impact on quality of life have
not been previously studied. In addition, little is known regarding the expression of immune
markers in CNS sarcoidosis and the association of such markers with disease activity and
response to treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore